Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners HSA Plus 2026 Formulary Coverage | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealthPartnersPolicy N/A

    HealthPartners HSA Plus 2026 Formulary (drug list)

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists medicines covered by the HealthPartners HSA Plus 2026 formulary, explains formulary structure and abbreviations, and describes utilization management programs (PA, ST, QL) and product-specific tier and requirement entries that apply to members covered under the HSA Plus plan.

    Policy Summary
    PayerHealthPartners
    PolicyHealthPartners HSA Plus 2026 Formulary (drug list)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization (PA) when the drug line indicates PA before dispensing to ensure coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026formulary year
    7defined drug tiers
    6 fillstrial program limit
    PAfrequent requirement
    multiplequantity limits

    Formulary Coverage & Utilization Management

    Utilization Management Criteria (general)

    Formulary coverage and utilization management rules

    Prior Authorization: Drugs marked PA require prior authorization; coverage may be denied if PA is not obtained.

    Failure to obtain PA may result in the drug not being covered under the pharmacy benefits (see documentation requirements).

    Step Therapy: Drugs marked ST require trial of specified alternative medication(s) first; approval may be granted if alternatives have been tried or if failure/intolerance is documented.

    If alternatives have not been tried, prescriber must request approval for coverage at the stated copay/coinsurance.

    Quantity Limits: Drugs with QL have a maximum quantity per fill or time period; requests above the QL will be reviewed for medical necessity and must include diagnosis, prior use within QL, alternatives tried, and evidence of efficacy/safety at the requested quantity.
    Policy Summary
    PayerHealthPartners
    PolicyHealthPartners HSA Plus 2026 Formulary (drug list)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization (PA) when the drug line indicates PA before dispensing to ensure coverage.
    SourceLink
    On This Page
    Formulary Coverage & Utilization ManagementDrug Listings, Codes, and ExamplesPrior Authorization, Step Therapy, Documentation & Denial RisksStep Therapy Rules & Affected ProductsQuantity Limits (Per Day / Per Fill / Period)Specialty Pharmacy, Infusion & Site RestrictionsAbbreviations & Table Codes

    QLs may be expressed per day, per 7/28/30/84/273 days, or per fill depending on the product.

    Trial Drug Program: Certain new medicines may be placed on a trial drug program: the first 6 fills may be limited to less than a month supply; if tolerated, the remainder of the month supply will be provided.first 6 fills

    When applicable, copay is limited to no more than one copay per one-month supply.

    Coverage contingent on PA/OP/QL compliance

    Coverage of listed analgesic products is subject to the following utilization controls as specified per product entry

    Formulary and utilization rules: Coverage requires adherence to the product-specific Drug Tier and any listed Requirements / Limits (PA, OP, QL).

    Each product row specifies whether PA, OP, and/or QL apply and the exact QL value (examples include OP; QL 120 per 1 day for hydrocodone solution; OP; QL 8 per 1 day for many tablets; PA; OP; QL 20 per 1 day for oxycodone-acetaminophen solution).

    Coverage with PA/QL/S conditions

    Formulary coverage with utilization controls

    Formulary entries: Each listed product is subject to the coverage tier and the specific requirement/limit noted (PA, QL, S).

    Apply PA when present; do not exceed the stated QL; specialty-designated (S) products require specialty pharmacy or program handling and may require enrollment or site-specific administration.

    Items designated NF (Non‑Formulary) in the drug table are not part of the plan formulary and frequently require prior authorization (PA) or may be excluded from coverage absent an approved PA. Specific NF entries and their PA/QL designations appear throughout the formulary (for example: VIVJOA — Drug Tier = NF; Requirements / Limits = PA; QL (18 per 84 days)), so providers should check each product row for NF status and any associated utilization controls before dispensing.

    Within the excerpted table there are no explicit clinical exclusion criteria listed (for example, the opioid and analgesic product rows show tier and utilization controls but do not state clinical exclusions). Any clinical exclusions would be documented elsewhere in the full policy; therefore coverage determinations in this fragment are driven by the product-level flags (PA, QL, OP, etc.) rather than stated exclusion rules.

    This table segment does not set out specific clinical exclusions; rather, coverage for each product is conditional on meeting the product's listed utilization controls such as PA, QL, and S. For example, coagulation agents like ARIXTRA entries are Drug Tier = NF and show Requirements / Limits = PA; QL (strength‑specific QL per 30 days), indicating that approval and adherence to quantity limits determine coverage.

    Within the provided portion of the document there are no statements declaring items as 'not medically necessary'. The excerpt focuses on formulary tiers and utilization management flags (PA, QL, S, ST) and does not include NMN language in these chunks.

    In the analgesic/opioid listings shown here there are no explicit 'not medically necessary' (NMN) rulings included. The rows specify tier, OP/PA/QL and other controls but do not label any item as NMN within this excerpt; coverage decisions depend on meeting the listed utilization requirements.

    The coagulation and specialty therapy table excerpt does not present any Not Medically Necessary (NMN) rules. Instead, it documents utilization controls such as PA, QL and S for each formulation (for example, multiple factor products show Requirements / Limits = PA; S), and coverage is applied according to those controls rather than NMN statements.

    Drug Listings, Codes, and Examples

    Prior Authorization, Step Therapy, Documentation & Denial Risks

    Prior Authorization

    Prior Authorization Required — Prior Authorization, Step Therapy, Documentation & Denial Risks

    Many medicines listed on the drug table require prior authorization (PA) before they will be covered under HealthPartners pharmacy benefits. This includes high-tier antivirals (for example, hepatitis C regimens such as HARVONI, MAVYRET, EPCLUSA/SOFOSBUVIR-VELPATASVIR and similar agents), numerous specialty and oncology therapies, many coagulation and infusion products, and selected extended‑release or other specified formulations. Failure to obtain required PA, to meet specialty/oncology program designations (S, ONC), or to comply with quantity limits (QL) and step therapy (ST) rules may result in denial of coverage.

    • Prior authorization (PA) is required for many listed products — providers must obtain PA before dispensing to avoid claim denial.
    • High‑tier antivirals and hepatitis C therapies (e.g., HARVONI, SOFOSBUVIR‑VELPATASVIR, SOVALDI, EPCLUSA, MAVYRET, GENVOYA/related regimens) are frequently designated PA and often S (specialty).
    • Oncology and antineoplastic agents commonly carry combined requirements: PA; ONC (oncology benefit); S (specialty); TD (trial drug) and QL (quantity limits).
    • Coagulation factor concentrates and many infusion therapies require PA and are often dispensed through specialty channels (PA; S) with specific QL or per‑period caps.
    • Certain formulations — extended‑release opioids, extended‑release neurologic agents, and specific specialty formulations (e.g., sodium oxybate, XYREM/XYWAV) — are subject to PA and QL.
    • Quantity limits (QL) are enforced (examples: PAXLOVID, oseltamivir dose‑packs, many antivirals and specialty inhalation/nebulized products); requests above QL will be reviewed for medical necessity and may be denied or require clinical justification.
    • Step therapy (ST) applies where noted (e.g., TRINTELLIX, some zolpidem extended‑release products); some entries show 'S' indicating step/specialty program requirements — however, many entries do not contain explicit step sequences.
    • Specialty drug documentation: products marked 'S' often require specialty pharmacy dispensing, additional clinical documentation, and PA submission that demonstrates medical necessity and prior steps when applicable.
    • Documentation expectations: PA requests and overrides for QL or ST must include supporting clinical information — diagnosis, prior therapies tried/failed, evidence of response or need for quantities beyond standard QL, and rationale for specialty/oncology exceptions.
    • Denial triggers: absence of an approved PA, exceeding QL without justification, failure to meet ONC/S/TD program criteria, or not satisfying step therapy requirements may result in claim denial or non‑coverage.
    • Operational note: providers should follow HealthPartners' PA submission process and include all requested supporting documentation to expedite decisions; failure to include required documentation may delay or prevent approval.

    Step Therapy Rules & Affected Products

    RequirementDescription
    Try specified alternate medication(s) first before coverage of ST-listed drug
    Per table header and definitions, drugs marked 'ST' require members to try one or more specified alternatives first; if alternatives have not been tried approval (prior authorization) is required for coverage at the lowest copay/coinsurance.
    Example DrugsFlag / Implication
    HARVONI; EPCLUSA; MAVYRET
    Listed with 'PA; S' — indicates prior authorization plus specialty management or step/specialty program handling may apply
    ObservationImplication for Authorization
    Many oncology agents carry ONC and TD flags (examples: BOSULIF, CABOMETYX, CALQUENCE).
    ONC/TD flags imply oncology-specific prior authorization and may indicate specialty program or step requirements; explicit step sequences are not provided in this excerpt.
    When 'S' AppearsProvider Action / Documentation
    Entries marked with 'S' (e.g., AUSTEDO XR titration kit; dalfampridine; DAYBUE) denote step therapy or specialty program indicators.
    Prescribers must document prior treatment history, including trials and failures or intolerance of required prior therapies, when 'S' is indicated to support authorization requests.
    Product ListingControls Noted
    Numerous products in the excerpt show 'PA' and 'QL' (e.g., VYSCOXA, HORIZANT) without any explicit 'ST' step edits shown.
    These entries are controlled by prior authorization and quantity limits but no step therapy sequence is defined in the provided excerpt.
    DrugFormulary Flag / Meaning
    TRINTELLIX (oral tablet 5, 10, 20 mg)
    Requirements / Limits = ST; QL (1 per 1 day) — entry explicitly marked 'ST', indicating step therapy applies per formulary table.
    ProductFlag / Implication
    zolpidem oral tablet, extended release multiphase (12.5 mg, 6.25 mg)
    Requirements / Limits = ST; QL (1 per 1 day) — marked 'ST' indicating step therapy is required prior to coverage.
    ExamplesRequirements / Limits
    Coagulation factor concentrates and specialty infusions (e.g., ADVATE, ADYNOVATE, AFSTYLA)
    Requirements / Limits = PA; S — entries indicate prior authorization plus specialty (S) program or step requirements for these high-tier products.
    SummaryPolicy Note
    No explicit multi-step therapy sequences are provided in this excerpt; product rows instead show individual controls (PA, QL, S) per product.
    Apply prior authorization when 'PA' is indicated, observe quantity limits (QL), and follow specialty handling requirements (S); specific step algorithms are not defined here.

    Quantity Limits (Per Day / Per Fill / Period)

    inv-133: nystatin oral suspension — 480
    Most actionable QL to check firstCheck the product line for explicit 'Requirements / Limits' (PA, QL, S, AL) and apply the stated QL exactly — e.g., VIVJOA QL (18 per 84 days); Nystatin suspension QL (480 per fill)
    Where to find limitsQuantity limits are listed on each product row in the formulary table (see 'Requirements / Limits' column)
    DocumentationRequests above QL will be reviewed for medical necessity and require supporting documentation (diagnosis, prior therapy) per policy
    inv-134: VIVJOA — 18
    ProductVIVJOA oral capsule 150 mg
    Quantity limit18 per 84 days
    RequirementsPA required; listed as NF in table
    inv-135: EDURANT PED (pediatric formulation) — 6
    ProductEDURANT PED oral tablet for suspension 2.5 mg
    Quantity limit6 per 1 day
    ContextPediatric formulation — QL applied per day as listed
    inv-136: PAXLOVID, oseltamivir, tembexa, others — various QL values included (examples listed)
    Examples includedPAXLOVID, oseltamivir, TEMBEXA and others have varied QL values (examples: PAXLOVID QL 4 or 6 per 1 day; oseltamivir QL 10 or 20 per fill; TEMBEXA QL 65 per 8 days)
    Check product rowEach antiviral entry shows its specific QL in the 'Requirements / Limits' column
    Denial riskExceeding QL may trigger denial or require override/documentation
    inv-137: TOBI INHALATION SOLUTION FOR NEBULIZATION 300 MG/5 ML — QL (5 per 1 day)
    ProductTOBI inhalation solution for nebulization 300 mg/5 ml
    Quantity limitQL (5 per 1 day)
    RequirementsPA; S indicated for inhaled antibiotic formulations
    inv-138: ORLYNVAH ORAL TABLET 500-500 MG — QL (10 Per fill)
    ProductORLYNVAH oral tablet 500-500 mg
    Quantity limitQL (10 Per fill)
    RequirementsPA required; listed as NF
    inv-139: AVMAPKI-FAKZYNJA ORAL COMBO PACK 0.8-200 MG — QL (66 per 28 days)
    ProductAVMAPKI-FAKZYNJA oral combo pack 0.8-200 mg
    Quantity limitQL (66 per 28 days)
    RequirementsPA; ONC; S — oncology/specialty combo pack example
    inv-140: everolimus (antineoplastic) oral tablet — QL (1 per 1 day)
    Producteverolimus (antineoplastic) oral tablet
    Quantity limitQL (1 per 1 day) [strength-dependent examples exist]
    RequirementsPA; ONC; TD; S (per antineoplastic listings)
    inv-141: DAURISMO ORAL TABLET — QL indicated where present (examples: QL (3 per 1 day))
    ProductDAURISMO oral tablet (glasdegib)
    Quantity limitQL indicated where present (examples include QL (3 per 1 day) for some strengths)
    RequirementsPA; ONC; TD; S as listed for antineoplastics
    inv-142: IBRANCE — QL (21 per 28 days)
    ProductIBRANCE (palbociclib) oral capsule/tablet
    Quantity limitQL (21 per 28 days)
    RequirementsPA; ONC; S — oncology oral therapy example
    inv-143: PEMAZYRE — QL (14 per 21 days)
    ProductPEMAZYRE oral tablet
    Quantity limitQL (14 per 21 days)
    RequirementsPA; ONC; S — listed in antineoplastic section
    inv-144: PIQRAY — QL (1–2)
    ProductPIQRAY oral tablet
    Quantity limitQL (1–2 per 1 day depending on dosing regimen)
    RequirementsPA; ONC; S — dosing-dependent QL shown in table
    inv-145: PEMAZYRE — QL (14)
    ProductPEMAZYRE oral tablet (repeat)
    Quantity limitQL (14 per 21 days) — reiterated in table
    ContextShown to emphasize consistent QL across entries for same product
    inv-146: pomalidomide / POMALYST — QL (21)
    Productpomalidomide / POMALYST oral capsule
    Quantity limitQL (21 per 28 days)
    RequirementsPA; ONC; S — typical cycle-based QL for antineoplastics
    inv-147: ROZLYTREK (200 mg) — QL (3)
    ProductROZLYTREK oral capsule 200 mg
    Quantity limitQL (3 per 1 day)
    RequirementsPA; ONC; TD; S — strength-specific QL noted
    inv-148: VENCLEXTA (various strengths) — varies (e.g., 2 per 1 day; 6 per 1 day; 1 per 135 days for starting pack)
    ProductVENCLEXTA oral tablets (various strengths)
    Quantity limitsVaries by strength (examples: 2 per 1 day; 6 per 1 day; starting pack QL 1 per 135 days)
    RequirementsPA; ONC; S — follow strength-specific QL in table
    inv-149: VITRAKVI — QL (2 or 6 or 10)
    ProductVITRAKVI oral capsule/solution
    Quantity limitsQL (2 per 1 day; 6 per 1 day; 10 per 1 day) depending on formulation/strength
    RequirementsPA; ONC; TD; S — multiple strength-based QLs listed
    inv-150: DIACOMIT oral capsule 250 mg — 12
    ProductDIACOMIT oral capsule 250 mg
    Quantity limit12 per 1 day
    RequirementsPA; S — high per-day QL for pediatric/epilepsy formulations
    inv-151: DIACOMIT oral capsule 500 mg — 6
    ProductDIACOMIT oral capsule 500 mg
    Quantity limit6 per 1 day
    RequirementsPA; S — strength-differentiated QL
    inv-152: diazepam rectal kit — 2
    ProductDiazepam rectal kit
    Quantity limit2 per 30 days
    RequirementsListed with QL (2 per 30 days) in table
    inv-153: FYCOMPA oral suspension 0.5 mg/mL — 8
    ProductFYCOMPA oral suspension 0.5 mg/mL
    Quantity limit8 per 1 day
    RequirementsPA; QL as listed for suspension formulation
    inv-154: FYCOMPA oral tablet 10-12-4-6-8 mg — 1
    ProductFYCOMPA oral tablet (10,12,4,6,8 mg)
    Quantity limit1 per 1 day (for listed tablet strengths)
    RequirementsPA; QL indicated per tablet strengths
    inv-155: Example quantity limits — includes examples like QL (1 per 1 day), QL (2 per 1 day), QL (70 per 28 days), QL (28 per 273 days)
    Product examplesGabapentin capsules (100 mg, 300 mg) — QL 12; 400 mg — QL 9; 600 mg tablet — QL 6
    Formulation guidanceOral solutions and suspensions may have different per-day QLs (e.g., NEURONTIN solution QL 72 per 1 day)
    Check tableApply the exact QL per formulation/strength as listed in the entry
    inv-156: Per-day quantity limits — examples include 120 per 1 day; 8 per 1 day; 2 per 1 day
    Representative per-day QLs120 per 1 day (hydrocodone-acetaminophen solution); 8 per 1 day (hydrocodone-acetaminophen tablets); 2 per 1 day (hydromorphone 8 mg)
    ApplicationPer-day QLs vary by formulation and strength — verify product row
    Denial riskExceeding per-day QL may lead to denial or require override/documentation
    inv-183: SPRAVATO NASAL SPRAY — QL (4 per 7 days for 56 mg; QL 6 per 7 days for 84 mg)
    ProductSodium oxybate oral solution 500 mg/ml
    Quantity limitQL (18 per 1 day)
    RequirementsPA; S indicated for specialty handling
    inv-184: XYREM / XYWAV oral solution — QL (18 per 1 day)
    ProductXYREM / XYWAV oral solution 500 mg/mL / 0.5 g/mL
    Quantity limitQL (18 per 1 day)
    RequirementsPA; S — listed as specialty and PA required
    inv-195: Eliquis DVT-PE TREAT 30D START (5 mg pack, 74 tabs) — 74
    Representative QL thresholdsEliquis DVT-PE treat pack QL 74 per 30 days; Xarelto DVT-PE treat QL 51 per 30 days; anticoagulant pellets/packs show per-day limits (e.g., 2 per day; 4 per day)
    Where listedThese QLs appear in the 'Requirements / Limits' column of coagulation therapy entries
    ActionVerify pack vs. tablet formulations as QL differs by presentation

    Specialty Pharmacy, Infusion & Site Restrictions

    Note
    Note
    Note
    Note
    Note

    Abbreviations & Table Codes